Prognosticators of osimertinib treatment outcomes in patients with EGFR-mutant non-small cell lung cancer and leptomeningeal metastasis

Chiang, Chi‐Lu; Ho, Hsiang‐Ling; Yeh, Yi‐Chen; Lee, Cheng‐Chia; Huang, Hui‐Chun; Shen, Ching-Hui; Luo, Yung‐Hung; Chen, Yuh‐Min; Chiu, Chao‐Hua; Chou, Teh-Ying

doi:10.1007/s00432-022-04396-1

Cited by 5 publications

(1 citation statement)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, ctDNA research is focused on analyzing multiple mutation information, including EGFR, ALK, and KRAS, to assess the prognosis and disease recurrence of lung cancer patients [ 199 ]. Detecting EGFR mutations in lung cancer using ctDNA allows for the assessment of various clinical information, such as the response to ositinib therapy, survival time, and the risk of distant metastasis in lung cancer [ 200 ]. Perioperative ctDNA analysis can detect MRD of resectable NSCLC earlier than conventional radiological imaging, providing a means to monitor tumor recurrence and metastasis [ 201 ].…”

Section: Clinical Application Potential Of Liquid Biopsy In Lung Cancermentioning

confidence: 99%

Liquid biopsy techniques and lung cancer: diagnosis, monitoring and evaluation

Ren,

Fei,

Qiu

et al. 2024

J Exp Clin Cancer Res

View full text Add to dashboard Cite

Lung cancer stands as the most prevalent form of cancer globally, posing a significant threat to human well-being. Due to the lack of effective and accurate early diagnostic methods, many patients are diagnosed with advanced lung cancer. Although surgical resection is still a potential means of eradicating lung cancer, patients with advanced lung cancer usually miss the best chance for surgical treatment, and even after surgical resection patients may still experience tumor recurrence. Additionally, chemotherapy, the mainstay of treatment for patients with advanced lung cancer, has the potential to be chemo-resistant, resulting in poor clinical outcomes. The emergence of liquid biopsies has garnered considerable attention owing to their noninvasive nature and the ability for continuous sampling. Technological advancements have propelled circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), extracellular vesicles (EVs), tumor metabolites, tumor-educated platelets (TEPs), and tumor-associated antigens (TAA) to the forefront as key liquid biopsy biomarkers, demonstrating intriguing and encouraging results for early diagnosis and prognostic evaluation of lung cancer. This review provides an overview of molecular biomarkers and assays utilized in liquid biopsies for lung cancer, encompassing CTCs, ctDNA, non-coding RNA (ncRNA), EVs, tumor metabolites, TAAs and TEPs. Furthermore, we expound on the practical applications of liquid biopsies, including early diagnosis, treatment response monitoring, prognostic evaluation, and recurrence monitoring in the context of lung cancer.

show abstract

Section: Clinical Application Potential Of Liquid Biopsy In Lung Cancermentioning

confidence: 99%